WO1993013049A1 - Emploi de l'effet immunoactivant de 3-naphthyloxy-2-hydroxy-propylamines, interessant specialement pour l'immunite cellulaire, par exemple contre infections virales - Google Patents
Emploi de l'effet immunoactivant de 3-naphthyloxy-2-hydroxy-propylamines, interessant specialement pour l'immunite cellulaire, par exemple contre infections virales Download PDFInfo
- Publication number
- WO1993013049A1 WO1993013049A1 PCT/CH1992/000242 CH9200242W WO9313049A1 WO 1993013049 A1 WO1993013049 A1 WO 1993013049A1 CH 9200242 W CH9200242 W CH 9200242W WO 9313049 A1 WO9313049 A1 WO 9313049A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radical
- naphthoxy
- radicals
- parts
- propanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
Definitions
- the present invention relates to the use as a medicament with immunoactivating effect in humans (and animals with neuroimmune regulation similar to that in humans) of homocyclic compounds and more particularly of naphthalene derivatives which have an immunoactivating effect and which are of particular interest for cellular immunity, for example for the treatment or prophylaxis of viral infections and certain immunodeficient diseases.
- This immunoactivating effect occurs by blockade of receptors on cells of the immune system, which facilitates the activation of the functional biochemical processes of the cell, thus imitating the regulation of the function of the immune system by the nervous system and more specifically the reverse regulation of immune activity by the tone of the sympathetic nervous system.
- Immunoactivation is by definition facilitated activation of the immune system in the presence of a foreign antigen.
- Animals with neuroimmune regulation analogous to that in humans are those with control of the immune system by hypothalamic nerve centers through on the one hand the hypothalamic-adrenocortical axis and on the other hand through the vegetative nervous system, especially the sympathetic nervous system.
- R 1 represents a hydrogen atom or an optionally substituted alkyl, cycloalkyl, alkenyl, aralkyl or alkanoyl radical
- R 2 represents a hydrogen atom or an optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl or aralkyl radical, or alternatively R 1 and R 2 form with the neighboring nitrogen atom a heterocyclic radical, optionally substituted
- R 3 , R 4 and R 5 which may be identical or different, represent hydrogen atoms or alkyl radicals
- the naphthalenic nucleus carries optionally one or more additional substituents, as well as their esters and their salts, but excluding the 1-amino-, 1-n-propylamino-, 1-n-butylamino-, 1-diethylamino-, 1-di-n -propylamino, 1-di-isopropyl-amino-, 1-di-n-butyla
- REPLACEMENT SHEET A preferred class of compounds includes those of naphthalene derivatives where R 1 , R 3 , R 4 and R 5 represent hydrogen atoms and R 2 has the meaning given to it above, and the naphthalenic ring optionally carries one or several additional substituents, as well as their esters and their salts, but excluding the 1-amino-, 1-n- propyla ⁇ -ino- and ln-butyl-amino-3- (1-naphthoxy) -2-propanols, 1-ethylamino-3- (2-naphthoxy) -2-propanol, their esters and their salts.
- R 1 may represent, for example, an alkyl or hydroxyalkyl radical of 5 carbon atoms maximum, for example the methyl ' , ethyl, s-butyl or 2-hydroxyethyl radical, or an aralkyl radical of 10 carbon atoms maximum, for example the acetyl radical.
- R 2 can represent, for example, an alkyl radical of 20 carbon atoms at most, for example the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, l-methyloctyl or radical 1-methylhexadecyl, or an alkyl radical of 10 carbon atoms maximum carrying one or more hydroxy radicals or substituted ino radicals, for example alkylamino, di-a-kylamino or heterocyclic radicals, such as alkylamino or dial_yla__ino radicals of 6 atoms of carbon at most or heterocyclic radicals of 6 atoms in the cycle at most, such as the dimethylamino or morpholino radicals, or alkoxy radicals, for example the alkoxy radicals of S carbon atoms at most, such as the methoxy radicals or n-propoxy, or alkoxyalkoxy radical
- R 2 may represent an aralkyl radical of 15 carbon atoms at most, optionally substituted, for example, by one or more alkoxy radicals, such as alkoxy radicals of 5 carbon atoms at most, such as the methoxy radical.
- R 2 for a substituted alkyl radical or substituted or unsubstituted aralkyl are the radicals:
- R 2 represents a cycloalkyl, alkenyl or alkynyl radical of 10 carbon atoms maximum, for example the cyclopentyl, allyl or 1-methyl-2-propynyl radical.
- the group -NR J R 2 representing a heterocyclic radical can be, for example, a heterocyclic nitrogen radical of S or 6 atoms optionally substituted, for example the pyrrolidino, piperidino or morpholino radical optionally substituted by one or more alkyl radicals of S atoms of carbon at most, like the methyl radical.
- R 3 , R 4 and R 5 representing alkyl radicals can be, for example, alkyl radicals of 5 carbon atoms at most, such as the methyl radical.
- Suitable substituents of the naphthalenic nucleus are, for example, halogen atoms, for example chlorine or bromine atoms, or alkyl or hydroxyalkyl radicals of 5 carbon atoms at most, for example the methyl radical or 1-hydroxyethyl, or acyl radicals, for example alkanoyl radicals of up to 6 carbon atoms, for example the acetyl radical, or sulfamoyl radicals, optionally substituted, for example dialkylsulfamoyl radicals of up to 10 carbon atoms, such as the dimethylsulfamoyl radical.
- halogen atoms for example chlorine or bromine atoms
- acyl radicals for example alkanoyl radicals of up to 6 carbon atoms, for example the acetyl radical, or sulfam
- Naphthalenic derivatives of particular interest are, for example, l-isopr_pylan_ ⁇ -3- (l-naphthoxy) -2-propanol, le-1 -t-butylamino-3- (l-naphthoxy) -2-propanol, l- (2-hydroxy-1,1-dimethylet ylamino) -3- (l-naphthoxy) -2-propanol, l- (l-memyl-3-phenylpropylamino) -3- (l-naphthoxy) -2- propanol, 1 -s-butylamino-3- (l-naphthoxy) -2-propanol, l- (l-memyloctylajnino) -3- (l-naphthoxy) -2-propanol, l- (l, l- dime ⁇ yl-3-phenylpropylarnino
- Suitable esters of these naphthalene derivatives are, for example, the Q-esters of acids of formula R 6 .COOH where R 6 represents an optionally substituted alkyl, alkenyl or aryl radical, for example an alkyl or alkenyl radical of 20 carbon atoms at most, or an aryl radical of 10 carbon atoms at most, for example the radical
- Suitable salts of these naphthalenic derivatives are the acid addition salts, for example derived from inorganic acids, such as hydrochlorides, hydrobromides, phosphates or sulfates, or organic acids such as oxalates, lactates, tartrates, acetates, salicylates, citrates, benzoates, naphthoates, o-acetoxybenzoates, adipates, maleates or 1,1-methylene-bis-2-hydroxy-3-naphthoates or also of sulfonated polystyrene resins such as "Zeo- Karb "225.
- Relatively insoluble salts for example l, 1'-methylène-bis-2-hydroxy-3-naphthoates, are interesting because they ensure a high concentration of the drug in the blood for a long time.
- a process for the preparation of naphthalene derivatives comprises the reaction of a halogenated compound of formula:
- R 3 , R 4 and R 5 have the meanings which have been given to them above, and the naphthalenic nucleus optionally carries one or more additional substituents, with an ine, of formula NH ⁇ 2 , where R 1 and R 2 have the meanings given to them above.
- X can represent, for example, a chlorine or bromine atom.
- the reaction can advantageously be accelerated or completed by heating.
- R 3 , R 4 and R 5 have the meanings given to them above and the naphthalene nucleus optionally carries one or more additional substituents with an amine of formula NEER i R 2 , where R 1 and R 2 have the meanings given to them above.
- This process can be carried out in a diluent or a solvent such as ethanol and can be accelerated or completed by heating.
- naphthalenic nucleus can carry one or more additional substituents, with a compound of formula:
- R 1 , R 2 , R 3 , R 4 , R 5 and X have the meanings given to them above.
- reaction of a naphthol and a halogen derivative can advantageously be carried out in the presence of an acid acceptor, but as a variant, an alkali metal derivative of naphthol, for example the sodium or potassium derivative , may be the starting compound
- R 1 represents a hydrogen atom and R 2 a radical of formula -CHR 7 R 8 , where R 7 represents a hydrogen atom or an alkyl or cycloalkyl radical, alkenyl, alkynyl, aryl or aralkyl optionally substituted, and R 8 represents an alkyl, cycloalkyl, alkenyl, alkynyl, aryl or aralkyl radical optionally substituted, or else R 7 and R 8 form with the neighboring carbon atom an optionally substituted cycloalkyl radical , according to which an amino derivative of formula is reacted under reduction conditions:
- R 3 , R 4 and R 5 have the meanings which have been given to them above and the naphthalene ring optionally carries one or more additional substituents, with a carbonyl compound of formula R 7 .CO.R 8 , where R 7 and R 8 have the meanings given to them above.
- R 7 represents an alkyl, cycloalkyl, alkenyl, alkynyl, aryl or aralkyl radical, optionally substituted, in an excess of this starting carbonyl compound, or else the presence of an alkaline borohydride, for example sodium borohydride in an inert diluent or solvent such as aqueous methanol and or in an excess of the starting carbonyl compound
- R 7 and or R 8 represent an optionally substituted alkenyl or alkynyl radical and qu we do not wish to reduce a corresponding optionally substituted alkyl radical by this process, it is necessary to have recourse, as may be noted, to suitable reduction conditions, for example adhesives created by the presence of sodium borohydride, ⁇ should be noted, in addition, that the starting amino derivatives can be formed in situ, for example by reduction of alpha-diazo-ketones, alpha-azidoketones and alpha
- a process for the preparation of those of naphthalenic derivatives where R 1 represents a hydrogen atom comprises the hydrogenolysis of a compound of formula:
- R 9 represents a hydrogenolysable radical, and the naphthalenic ring optionally carries one or more additional substituents.
- R 9 may represent an alpha-arylalkyl radical of 10 carbon atoms at most, for example the benzyl radical.
- This hydrogenolysis can be carried out by catalytic hydrogenation, for example in the presence of a platinum or palladium on carbon catalyst optionally in a diluent or an inert solvent such as ethanol.
- naphthalene derivatives where the naphthalenic nucleus carries as a substituent a hydroxyalkyl radical
- the corresponding compound is reduced where the naphthalenic nucleus carries as a substitute the corresponding oxoalkyl radical
- An appropriate oxoalkyl radical is, for example an oxoalkyl radical of 20 carbon atoms maximum, for example an alkanoyl radical of 20 carbon atoms maximum, such as the acetyl radical.
- a suitable reducing agent is, for example, sodium borohydride.
- acylating agents are, for example, acyl halides and acid anhydrides, such as acetic anhydride and benzoyl chloride. Acylation can be carried out in a diluent or a solvent which, when an acid anhydride is used, is advantageously the acid from which the anhydride is derived.
- a process for the preparation of those of the naphthalene derivatives where R 1 represents an alkanoyl radical comprises the isomerization of an ester of formula:
- R 2 , R 3 , R 4 and R 5 have the meanings given to them above and R 10 represents an alkyl radical, for example an alkyl radical of 5 carbon atoms at most, and the naphthalenic ring optionally carries one or more additional substituents.
- the isomerization can be carried out by reacting the ester with a strong base, such as an alkali metal hydroxide, for example sodium hydroxide, advantageously in a diluent or a solvent such as methanol.
- a strong base such as an alkali metal hydroxide, for example sodium hydroxide
- a mixture of 4.4 parts of 1-chloro-3- (1-naphthoxy) -2-propanol and 16 parts of isopropylamine is heated at 70-80 ° C for 10 hours in a sealed container.
- the container is cooled and its content is added with 50 parts of water.
- the mixture is acidified using 2N hydrochloric acid, then washed with 50 parts of ether.
- the aqueous phase is discolored using charcoal, then poured into 50 parts of 2N sodium hydroxide solution at 0 ° C.
- the mixture is filtered.
- the solid residue is washed with water, dried and recrystallized from cyclohexane. This gives l-isopropylamino-3- (l-naphthoxy) -2-propanol, melting point 96 ° C.
- a mixture of 2.3 parts of l-chloro-3- (l-naphthoxy) -2-propanol and 2.6 parts of l-methyl-3-phenylpropyl_jn_ne is heated at 90-100 ° C for 10 hours.
- the mixture is then cooled, diluted with 50 parts of 2N sodium hydroxide and 50 parts of ether.
- the mixture is separated and the ethereal phase is dried over anhydrous magnesium sulfate, then filtered and evaporated.
- the residue is dissolved in 50 parts of ethyl acetate and added with a solution of hydrochloric acid in ether.
- a mixture of 1.84 parts of 1,2-epoxy-3-naphthoxy-propane and 1.7 parts of isopropylamine is heated at reflux for 16 hours.
- the mixture is acidified with 25 parts of 2N hydrochloric acid and washed with 50 parts of ether.
- the aqueous solution is then poured into 50 parts of a 2N sodium hydroxide solution at 0 ° C and the mixture obtained is filtered.
- the solid residue is washed with water and dried, then recrystallized from cyclohexane. This gives l-_soprOpyla_nino-3- (l-n_phthoxy) -2-propanol, melting point 96 ° C.
- the base can be converted into the hydrochloride as follows: 4.65 parts of the base are dissolved in 30 parts of hot acetone. 2 parts of ION hydrochloric acid are then added to the hot solution. The mixture is cooled and then filtered. The solid residue is washed with acetone and dried. The solid is recrystallized from propanol to give l-isc ⁇ ropylarnino-3- (l-naphthoxy) -2-propanol hydrochloride, melting point 163 ° C.
- a mixture of 2.5 parts of 2-bromo-4- (naphthoxy) -3-butanol and 10 parts of isopropylamine is heated at 100 ° C for 10 hours in an autoclave. The mixture is then evaporated under reduced pressure and the residue is acidified using 25 parts of 2N hydrochloric acid. Charcoal is added and the mixture is stirred and then filtered. The filtrate is poured into 50 parts of 2N sodium hydroxide solution and the mixture obtained is extracted using 50 parts of ether. The ethereal extract is dried over anhydrous magnesium sulphate then filtered and the filtrate is acidified using a solution of hydrochloric acid in ether.
- the starting 2-bromo-4- (naphthoxy) -3-butanol can be obtained in the following way: A stirred solution of 3 parts of 2-bromo-4- (1-naphthoxy) -3-butanone in 20 parts of methanol at -5 ° C. 0.5 part of sodium borohydride is added. The mixture is stirred for 2 hours at 0 ° C. and then poured onto 100 parts of ice. 50 parts of ether are then added and the mixture obtained is separated. The ethereal phase is dried over anhydrous magnesium sulfate and then evaporated. The residue consists of 2-bromo-4- (1-naphthoxy) -3-butanol. 2- bromo-4- (l-naphthoxy) -3-butanone can be obtained as follows
- REPLACEMENT SHEET add a solution of 10 parts of 1-naphthoxyacetyl chloride in 150 parts of ether. The mixture is stirred at 0 ° C for 3 hours, then at room temperature for 18 hours. The mixture is then stirred and cooled to -5 ° C and added with 20 parts of 40% hydrobromic acid. The mixture is stirred at -5 ° C for 30 minutes. The mixture is separated and the ethereal phase is dried over anhydrous magnesium sulfate. The mixture is filtered and the filtrate is evaporated under reduced pressure. The residue is extracted using 20 parts of cyclohexane and the extract is filtered. The filtrate is evaporated under reduced pressure and its residue consists of 2-bromo-4- (1-naphthoxy) -3-butanone.
- a solution of 0.46 part of sodium in 20 parts of ethanol is added to 2.42 parts of l-chloiO-3- (N-ben_yl-N-isoprt) pyl_-nino) -2-propanol, then the mixture is added with 1.44 parts of 1-naphthol.
- the mixture is heated under pressure at 100 ° C for 10 minutes in a sealed tube, then evaporated to dryness under reduced pressure.
- the residue is stirred with 50 parts of 2N hydrochloric acid and 50 parts of ether.
- the mixture is separated and the aqueous layer is made alkaline by the addition of a 2N sodium hydroxide solution.
- the alkaline solution is extracted three times with 100 parts of ether.
- a mixture of 0.3 parts of 3-bromo-1- (l-naphthoxy) -2-propanol and 5 parts of isopropylamine is heated for 10 hours at 100 ° C in a sealed container.
- the container is cooled and 10 parts of 2N hydrochloric acid are added to its content.
- the mixture is filtered and the filtrate is basified with a 2N sodium hydroxide solution, then stirred with 25 parts of ether.
- the mixture is separated and the ethereal phase is dried over anhydrous magnesium sulfate, then filtered.
- the filtrate is evaporated to dryness.
- the residue consists of l-isopr ⁇ pylamino-3- (l-naphthoxy) -2-propanol, melting point 96 ° C.
- the starting 3-bromo-l- (l-naphthoxy) -2-propanol can be obtained in the following way: A solution of 0.28 part of 3-bromo-l- (l-naphthoxy) -acetone in 5 parts of methanol is stirred and cooled to 0 ° C during the addition of 0.25 part of sodium borohydride. The mixture is then stirred for a further 30 minutes at 0 ° C. The mixture is poured onto ice, acidified with 2N hydrochloric acid and extracted with 20 parts of ether. The ethereal extract is dried over anhydrous magnesium sulfate and filtered, and the filtrate is evaporated to dryness. The residue consists of 3-bromo-1- (1-naphthoxy) -2-propanol. This compound has a characteristic absorption band in the infrared at 3450 cm * 1 .
- 3-bromo-1- (1-naphthoxy) acetone can be obtained in the following way: A solution of 10 parts of 1-naphthoxyacetyl chloride in 150 parts of ether is stirred and cooled to between -5 and 10 ° C for the addition over 30 minutes of a solution of 11 parts of diazomethane in 300 parts of ether. The solution is stirred for 2 hours at -5 ° C, then for another 18 hours at room temperature. The solution is then stirred and cooled to -10 ° C during the addition of 20 parts of 1 IN hydrobromic acid. The mixture is stirred for 30 minutes. The mixture is separated and the ethereal phase is dried over sulphate of
- REPLACEMENT SHEET anhydrous and filtered magnesium. The filtrate is evaporated to dryness and the residue is recrystallized from cyclohexane. 3-bromo-l- (l-naphthoxy) acetone is thus obtained, melting point 92-94 ° C.
- a mixture of 8 parts of 1-chloro-3-methyl-3- (1-naphthoxy) -2-butanol and 40 parts of isopropylamine is heated at 100 ° C for 10 hours in a sealed container.
- the excess isopropylamine is evaporated and the residue is dissolved in 100 parts of IN hydrochloric acid.
- the solution is washed with ether and the acidic aqueous solution is added with 20 parts of 8N sodium hydroxide solution.
- the mixture is extracted using 100 parts of ether and the ethereal extract is washed with water, then dried over anhydrous magnesium sulfate.
- the ethereal solution is evaporated to dryness.
- a solution of 70 parts of alpha- (1-naphthoxy) -isobutyryl chloride in 200 parts of ether is treated with an excess of diazomethane in ether at 0 ° C for 24 hours, then the ether and the excess diazomethane is evaporated.
- the residual gum is dissolved in 250 parts of ether and gaseous hydrochloric acid is passed into the solution at 0 ° C until saturation.
- the solution is stirred and gradually added 300 parts of ice.
- the mixture is separated and the ethereal solution is washed successively three times with 100 parts of water, three times with 150 parts of a 10% sodium carbonate solution and finally three times with 100 parts of water.
- the ethereal solution is dried over anhydrous magnesium sulfate, then evaporated. 10 parts of the residue are dissolved in 80 parts of methanol, the solution is stirred and 5 parts of sodium borohydride are added thereto at 0 ° C over 45 minutes. After 12 hours, the methanol is evaporated and the residue is stirred with 30 parts of ether and 20 parts of water. The mixture is separated, the ethereal solution is dried over anhydrous magnesium sulphate, then evaporated to dryness. 1-chloro-3-methyl-3- (l-naphthoxy) -butanoL is thus obtained in the form of an oil.
- Example 13 The process of Example 13 is repeated using 40 parts of t-butylamine instead of 40 parts of isopropylamine. This gives l-t-butylamino-3-methyl-3- (l-naphthoxy) -2-butanol hydrochloride, melting point 219-220 ° C.
- Example 13 The process of Example 13 is repeated using 8 parts of l-chloro-3- (l-naphth-oxy) -2-butanol instead of 8 parts of l-chloro-3-methyl-3- (l- naphthoxy) -2-butanol. This gives l-isopropylamino-3- (l-naphthoxy) -2-butanol hydrochloride, melting point 158-159 ° C.
- the starting l-chloro-3- (l-naphthoxy) -2-butanol can be obtained in the following way: A solution of 20 parts of alpha- (l-naphthoxy) propionic acid in 300 parts of chloroform and 16, 5 parts of thionyl chloride is heated at reflux for 3 hours, then the chloroform and the excess of thionyl chloride are evaporated. The oily residue consists of alpha- (l-naphthoxy) propionyl chloride. A solution of 20 parts of this oil in 100 parts of ether is treated with an excess of diazomethane in ether at 0 ° C for 16 hours then the ether and the excess diazomethane are evaporated.
- the residual gum is dissolved in 150 parts of ether and gaseous hydrochloric acid is passed into the solution at 0 ° C until saturation.
- the solution is stirred and gradually added with 200 parts of ice.
- the mixture is separated and the ethereal solution is washed successively three times with 50 parts of water, three times with 50 parts of a 10% solution of sodium carbonate and finally three times with 50 parts of water.
- the ethereal solution is dried over anhydrous magnesium sulfate, then evaporated to give chloromethyl-1- (l-naphthoxy) ethyl ketone, melting point 70-71 ° C [after recrystallization from petroleum ether (boiling range 60-80 ° C)].
- the aqueous phase is decanted and as much of the residue as possible is dissolved in 2N hydrochloric acid at 0 ° C.
- the solution is made alkaline with a 2N sodium hydroxide solution, then extracted with using 50 parts of ether.
- the ethereal extract is dried over anhydrous magnesium sul ⁇ fate, then filtered.
- To the filtrate is added a saturated solution of oxalic acid in ether until precipitation is substantially complete.
- the mixture is filtered and the solid residue is recrystallized from ethanol.
- 1-isopropyl-amino-methyl-2- (1-naphthoxy) ethyl acetate is thus obtained in the form of its acid oxalate, melting point 202-204 ° C.
- hydrochloric acid instead of oxalic acid, it is possible to use hydrochloric acid and obtain analogously l-isopropylaminomethyl-2- (l-naphthoxy) ethyl acetate in the form of its hydrochloride, melting point 170-171 ° C (after recrystallization from a mixture of ethanol and ethyl acetate).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO933680A NO933680D0 (no) | 1992-12-14 | 1993-10-13 | 3-naftyloksy-2-hydroksy-propylaminer |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH3795/91-6 | 1991-12-20 | ||
| CH379591 | 1991-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1993013049A1 true WO1993013049A1 (fr) | 1993-07-08 |
Family
ID=4263624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CH1992/000242 Ceased WO1993013049A1 (fr) | 1991-12-20 | 1992-12-14 | Emploi de l'effet immunoactivant de 3-naphthyloxy-2-hydroxy-propylamines, interessant specialement pour l'immunite cellulaire, par exemple contre infections virales |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0587823A1 (fr) |
| AU (1) | AU3079692A (fr) |
| CA (1) | CA2109224A1 (fr) |
| FI (1) | FI935056A0 (fr) |
| WO (1) | WO1993013049A1 (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420294A (en) * | 1988-06-03 | 1995-05-30 | Eli Lilly And Company | Cycloalkylaminoalkoxyindoles |
| WO2002024619A1 (fr) * | 2000-09-25 | 2002-03-28 | Btg International Limited | Composes d'amine |
| CN107556203A (zh) * | 2016-06-30 | 2018-01-09 | 康普药业股份有限公司 | 一种普萘洛尔的制备方法 |
| CN113336656A (zh) * | 2021-05-28 | 2021-09-03 | 常州康普药业有限公司 | 一种盐酸普萘洛尔的合成方法 |
| US11998013B1 (en) | 2023-09-01 | 2024-06-04 | King Faisal University | 1-(morpholin-4-yl)-3-(naphthalen-2-yloxy)propan-2-ol as an eco-friendly insecticidal agent against spodoptera littoralis (boisd.) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4026897A (en) * | 1974-01-31 | 1977-05-31 | Otsuka Pharmaceutical Company | 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives |
| EP0045334A1 (fr) * | 1980-08-04 | 1982-02-10 | Syva Company | Produits conjugués d'antigène et de propranolol et anticorps et procédé pour leur utilisation |
| US4329502A (en) * | 1978-08-28 | 1982-05-11 | Syva Company | Propranolol antigen conjugates and antibodies |
| EP0095639A2 (fr) * | 1982-05-27 | 1983-12-07 | Miles Laboratories, Inc. | Immunogènes du propranolol, leurs anticorps, dispositif pour tester et composés pour l'immunoessai du propranolol |
| US4652681A (en) * | 1982-04-15 | 1987-03-24 | Drug Science Foundation | Aminoalkoxy derivatives of propranolol for immunoassay applications |
| EP0288188A1 (fr) * | 1987-04-09 | 1988-10-26 | Eli Lilly And Company | 1-Phényl-3-naphtalényloxy-propénamines |
-
1992
- 1992-12-14 CA CA 2109224 patent/CA2109224A1/fr not_active Abandoned
- 1992-12-14 AU AU30796/92A patent/AU3079692A/en not_active Abandoned
- 1992-12-14 WO PCT/CH1992/000242 patent/WO1993013049A1/fr not_active Ceased
- 1992-12-14 EP EP19920924530 patent/EP0587823A1/fr not_active Withdrawn
-
1993
- 1993-11-15 FI FI935056A patent/FI935056A0/fi not_active Application Discontinuation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4026897A (en) * | 1974-01-31 | 1977-05-31 | Otsuka Pharmaceutical Company | 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives |
| US4329502A (en) * | 1978-08-28 | 1982-05-11 | Syva Company | Propranolol antigen conjugates and antibodies |
| EP0045334A1 (fr) * | 1980-08-04 | 1982-02-10 | Syva Company | Produits conjugués d'antigène et de propranolol et anticorps et procédé pour leur utilisation |
| US4652681A (en) * | 1982-04-15 | 1987-03-24 | Drug Science Foundation | Aminoalkoxy derivatives of propranolol for immunoassay applications |
| EP0095639A2 (fr) * | 1982-05-27 | 1983-12-07 | Miles Laboratories, Inc. | Immunogènes du propranolol, leurs anticorps, dispositif pour tester et composés pour l'immunoessai du propranolol |
| EP0288188A1 (fr) * | 1987-04-09 | 1988-10-26 | Eli Lilly And Company | 1-Phényl-3-naphtalényloxy-propénamines |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420294A (en) * | 1988-06-03 | 1995-05-30 | Eli Lilly And Company | Cycloalkylaminoalkoxyindoles |
| US5554640A (en) * | 1988-06-03 | 1996-09-10 | Eli Lilly And Company | Use of propanolamine derivatives as selective 5-HT1 antagonists |
| WO2002024619A1 (fr) * | 2000-09-25 | 2002-03-28 | Btg International Limited | Composes d'amine |
| CN107556203A (zh) * | 2016-06-30 | 2018-01-09 | 康普药业股份有限公司 | 一种普萘洛尔的制备方法 |
| CN107556203B (zh) * | 2016-06-30 | 2022-05-03 | 康普药业股份有限公司 | 一种普萘洛尔的制备方法 |
| CN113336656A (zh) * | 2021-05-28 | 2021-09-03 | 常州康普药业有限公司 | 一种盐酸普萘洛尔的合成方法 |
| CN113336656B (zh) * | 2021-05-28 | 2022-03-01 | 常州康普药业有限公司 | 一种盐酸普萘洛尔的合成方法 |
| US11998013B1 (en) | 2023-09-01 | 2024-06-04 | King Faisal University | 1-(morpholin-4-yl)-3-(naphthalen-2-yloxy)propan-2-ol as an eco-friendly insecticidal agent against spodoptera littoralis (boisd.) |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2109224A1 (fr) | 1993-06-21 |
| AU3079692A (en) | 1993-07-28 |
| EP0587823A1 (fr) | 1994-03-23 |
| FI935056A0 (fi) | 1993-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK5385A (en) | 1-(dihydroxyphenyl)-2-amino-ethanol derivatives; preparation, compositions and intermediates | |
| EP0251859A2 (fr) | Procédé de préparation d'imidazopyridines | |
| EP0522915B1 (fr) | Dérivés de pyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique | |
| EP0117779A1 (fr) | Dérivés de la pyridazine actifs sur le système nerveux central, procédé d'obtention et médicaments en contenant | |
| EP0025727B1 (fr) | Dérivés de l'indole, procédé pour leur préparation et médicaments les contenant | |
| EP0174242B1 (fr) | Dérivés de 1-(aminophényl)-2-amino-propanone, leur utilisation en thérapeutique et leur procédé de préparation | |
| EP0021857B1 (fr) | Dérivés de l'indole, leur préparation et medicaments les contenant | |
| WO1993013049A1 (fr) | Emploi de l'effet immunoactivant de 3-naphthyloxy-2-hydroxy-propylamines, interessant specialement pour l'immunite cellulaire, par exemple contre infections virales | |
| EP0063084B1 (fr) | Dérivés de phénéthanolamine, leur préparation et leur application en thérapeutique | |
| MC1357A1 (fr) | Derives de 2,3-indoledione | |
| FR2480286A1 (fr) | Nouveaux derives de theophyllinylmethyldioxolane, leurs procedes de preparation et leur application en therapeutique | |
| EP0426562B1 (fr) | Dérivés de 1-(4-aminophényl)-2-pipéridinopropanone, procédé de préparation et utilisation en thérapeutique | |
| EP0074903A2 (fr) | Dérivés d'amino-2 tétrahydro-1,2,3,4 naphtalène, leur préparation et leur application en thérapeutique | |
| EP0139921B1 (fr) | Dérivés de 2-phényléthylamine | |
| EP0183577B1 (fr) | Dérivés du thiadiazole actifs sur le système nerveux central, procédé d'obtension et compositions pharmaceutiques les contenant | |
| EP0143711A2 (fr) | Dérivés de N-(méthoxyphénacyl)-amine, utilisation notamment en thérapeutique et procédé de préparation | |
| FR2465733A1 (fr) | Nouveaux derives imidazolylethoxymethyliques de 1,3-dioxoloquinoleines utiles notamment comme medicaments antibacteriens et antifongiques, leur procede de preparation et compositions therapeutiques et formes pharmaceutiques les contenant | |
| US4259257A (en) | 1-Phenyl-2-amino-1,3-propanediol-N-aryloxyalkyl derivatives | |
| EP0017523B1 (fr) | Nouveaux dérivés du dithiépinno (1,4)(2,3-c)pyrrole, leur préparation et les médicaments qui les contiennent | |
| CA1271197A (fr) | Procede de preparation de derives du 4-phenylpropyl indole | |
| FR2584070A1 (fr) | Nouveaux derives de l'hydroxy alkoxy 4-phenyl propyl indole, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant. | |
| EP0004835A1 (fr) | Composés ethanolamine, procédés pour leur préparation, préparations pharmaceutiques les contenant et leur utilisation médicale | |
| CH627473A5 (fr) | Procede de preparation de nouveaux derives thiazoliques. | |
| FR2507180A1 (fr) | Nouvelles phenylalkylamines, leur preparation et leur application comme medicaments | |
| EP0275221B1 (fr) | Nouveaux dérivés du N-(1H-indol 4-yl) benzamide ainsi que leurs sels, leur application à titre de médicaments et les compositions les renfermant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP NO US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1992924530 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2109224 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 935056 Country of ref document: FI |
|
| WWP | Wipo information: published in national office |
Ref document number: 1992924530 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 1994 137164 Country of ref document: US Date of ref document: 19940819 Kind code of ref document: A |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1992924530 Country of ref document: EP |